US4461759A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Constant release rate solid oral dosage formulations of veropamil
Assignee: Verex Laboratories Inc
•
Filing: 1983-01-03
•
Granted: 1984-07-24
•
Expires: 2003-01-03
Abstract
Abstract A constant order release rate solid oral dosage formulation of verapamil or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of verapamil; from about 0.5 to 6.0 weight percent of an acid-retardant or hydrophobic cellulose derivative; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil: from about 1 to 20 weight percent of an acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a lubricant.
Inventors
- 👤 James M. Dunn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:31
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/275; A61K9/00; A61K9/20; A61K9/2004; A61P; A61P7/00; A61P7/10; A61P9/00; A61P9/04; A61K9/2009; A61K9/2013; A61K9/2022; A61K9/2027; A61K9/205; A61K9/2054
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
116 words
A constant order release rate solid oral dosage formulation of verapamil or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of verapamil or a pharmaceutically acceptable salt thereof; from about 0.5 to 6.0 weight percent of microcrystalline cellulose alone or with one or more acid-retardant, hydrophobic cellulose derivatives selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, and ethyl cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene, a pharmaceutically acceptable acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a tableting lubricant.
Claim 2
Dependent Claim
116 words
A constant order release rate solid oral dosage formulation of verapamil or a pharmaceutically acceptable salt thereof, said formulation comprising: a therapeutically effective amount of verapamil or a pharmaceutically acceptable salt thereof; from about 0.5 to 6.0 weight percent of microcrystalline cellulose alone or with one or more acid-retardant, hydrophobic cellulose derivatives selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, and ethyl cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene, a pharmaceutically acceptable acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 percent of a tableting lubricant.
Claim 3
Dependent Claim
10 words
The formulation of claim 1 wherein said drug is verapamil.
Claim 4
Dependent Claim
15 words
The formulation of claim 1 wherein said acid retardant cellulose derivative is cellulose acetate phthalate.
Claim 5
Dependent Claim
14 words
The formulation of claim 1 wherein said hydrogenated vegetable oil is hydrogenated cottonseed oil.
Claim 6
Dependent Claim
13 words
The formulation of claim 1 wherein said acrylic acid polymer is CARBOPOL-934P carbomer.
Claim 7
Dependent Claim
24 words
The formulation of claim 1 wherein said acid retardant cellulose derivative is cellulose acetate phthalate, and said hydrogenated vegetable oil is hydrogenated cottonseed oil.
Claim 8
Dependent Claim
10 words
The formulation of claim 6 wherein said drug is verapamil.
Claim 9
Dependent Claim
94 words
A sustained release verapamil tablet comprising 250 mg of verapamil or a pharmaceutically acceptable salt thereof; from about 0.5 to 6.0 weight percent of microcrystalline cellulose alone or in combination with one or more hydrophobic cellulose derivative selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, and ethyl cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1-20 weight percent of carboxypolymethylene, CARBOPOL-934P carbomer; from about 0.5-4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 weight percent of a tableting lubricant.
Claim 10
Dependent Claim
94 words
A sustained release verapamil tablet comprising 250 mg of verapamil or a pharmaceutically acceptable salt thereof; from about 0.5 to 6.0 weight percent of microcrystalline cellulose alone or in combination with one or more hydrophobic cellulose derivative selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, and ethyl cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1-20 weight percent of carboxypolymethylene, CARBOPOL-934P carbomer; from about 0.5-4.0 weight percent of fumed silicon dioxide and from about 0.4 to 3.0 weight percent of a tableting lubricant.
Claim 11
Dependent Claim
16 words
The sustained release verapamil tablet of claim 8 wherein said cellulose derivative is cellulose acetate phthalate.
Claim 12
Dependent Claim
18 words
The sustained release verapamil tablet of claim 8 wherein said hydrogenated vegetable oil is hydrogenated cotton seed oil.
Claim 13
Dependent Claim
26 words
The sustained release verapamil tablet of claim 8 wherein said cellulose derivative is cellulose acetate phthalate and said hydrogenated vegetable oil is hydrogenated cotton seed oil.
Claim 14
Dependent Claim
97 words
A constant release rate verapamil tablet comprising: a therapeutically effective amount of verapamil or a pharmaceutically acceptable salt thereof; from about 0.5 to 6.0 weight percent of an acid-retardant, hydrophobic cellulose derivative selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, and ethyl cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene, a pharmaceutically acceptable acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide; and from about 0.4 to 3.0 weight percent of a tableting lubricant.
Claim 15
Dependent Claim
97 words
A constant release rate verapamil tablet comprising: a therapeutically effective amount of verapamil or a pharmaceutically acceptable salt thereof; from about 0.5 to 6.0 weight percent of an acid-retardant, hydrophobic cellulose derivative selected from the group consisting of cellulose acetate phthalate, hydroxypropylmethyl cellulose phthalate, and ethyl cellulose; from about 2.5 to 35 weight percent of a hydrogenated vegetable oil; from about 1 to 20 weight percent of carboxypolymethylene, a pharmaceutically acceptable acrylic acid polymer; from about 0.5 to 4.0 weight percent of fumed silicon dioxide; and from about 0.4 to 3.0 weight percent of a tableting lubricant.
Claim 16
Dependent Claim
14 words
The verapamil tablet of claim 12 wherein said cellulose derivative is cellulose acetate phthalate.
Claim 17
Dependent Claim
15 words
The verapamil tablet of claim 12 wherein said hydrogenated vegetable oil is hydrogenated cottonseed oil.
Claim 18
Dependent Claim
24 words
The verapamil tablet of claim 12 wherein carboxypolymethylene, said cellulose derivative is cellulose acetate phthalate and said hydrogenated vegetable oil is hydrogenated cottonseed oil.
References Cited (Backward Citations)
US3577514A
Cited
GB1538123A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-24 | 1988-01-23 | 1988-07-24 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-24 | 1992-01-23 | 1992-07-24 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-24 | 1996-01-23 | 1996-07-24 | $7700.00 | Window Closed / Lapsed |